Calithera Biosciences Incorporated (NASDAQ:CALA) Short Interest Increased By 0.03%

September 17, 2017 - By Ellis Scott

 Calithera Biosciences Incorporated (NASDAQ:CALA) Short Interest Increased By 0.03%

Investors sentiment increased to 1.2 in 2016 Q4. Its up 0.44, from 0.76 in 2016Q3. It is positive, as 9 investors sold Calithera Biosciences Inc shares while 6 reduced holdings. 4 funds opened positions while 14 raised stakes. 5.98 million shares or 0.90% more from 5.92 million shares in 2016Q3 were reported.
Tfs Capital Limited Liability Corporation invested in 28,408 shares or 0.02% of the stock. Blackrock Fund Advsr reported 0% in Calithera Biosciences Inc (NASDAQ:CALA). The Ontario – Canada-based Manufacturers Life Com The has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). Bridgeway Capital Management Inc has invested 0.01% in Calithera Biosciences Inc (NASDAQ:CALA). Pennsylvania-based Susquehanna International Group Ltd Liability Partnership has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). 27,825 are owned by Comml Bank Of New York Mellon Corp. Oxford Asset has invested 0.01% in Calithera Biosciences Inc (NASDAQ:CALA). Rbf Cap Limited Liability invested 0.01% in Calithera Biosciences Inc (NASDAQ:CALA). Blackrock Institutional Company Na has 0% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 260,883 shares. Northern has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). Franklin Street Advsr Nc stated it has 124,580 shares. Jacobs Levy Equity has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). Vanguard Grp Inc has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). Blackrock Invest Mgmt Limited Company has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). Wells Fargo Mn stated it has 0% in Calithera Biosciences Inc (NASDAQ:CALA).

The stock of Calithera Biosciences Incorporated (NASDAQ:CALA) registered an increase of 0.03% in short interest. CALA’s total short interest was 2.92 million shares in September as published by FINRA. Its up 0.03% from 2.92M shares, reported previously. With 386,200 shares average volume, it will take short sellers 8 days to cover their CALA’s short positions. The short interest to Calithera Biosciences Incorporated’s float is 22.25%.

The stock decreased 0.66% or $0.1 on September 15, reaching $15.05. About 1.01M shares traded or 114.09% up from the average. Calithera Biosciences Inc (NASDAQ:CALA) has risen 278.82% since September 17, 2016 and is uptrending. It has outperformed by 262.12% the S&P500.

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $533.92 million. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It currently has negative earnings. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Calithera Biosciences Inc (NASDAQ:CALA) Ratings Coverage

Among 4 analysts covering Calithera Biosciences (NASDAQ:CALA), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Calithera Biosciences had 8 analyst reports since July 24, 2015 according to SRatingsIntel. On Tuesday, October 25 the stock rating was initiated by Citigroup with “Sell”. On Monday, June 12 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by H.C. Wainwright on Tuesday, March 28 with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Thursday, January 5. The firm has “Buy” rating given on Friday, July 24 by Citigroup. The company was upgraded on Tuesday, January 24 by Citigroup. As per Wednesday, March 9, the company rating was maintained by JMP Securities.

More notable recent Calithera Biosciences Inc (NASDAQ:CALA) news were published by: Globenewswire.com which released: “Incyte and Calithera Biosciences Announce Global Collaboration to Develop and …” on January 30, 2017, also Fool.com with their article: “Here’s Why Calithera Biosciences Stock Gained as Much as 16.4% Today” published on May 10, 2017, Globenewswire.com published: “Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recent …” on August 08, 2017. More interesting news about Calithera Biosciences Inc (NASDAQ:CALA) were released by: Globenewswire.com and their article: “Calithera Biosciences Reports First Quarter 2017 Financial Results and Recent …” published on May 09, 2017 as well as Nasdaq.com‘s news article titled: “Earnings Estimates Moving Higher for Calithera Biosciences (CALA): Time to Buy?” with publication date: September 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.